ORIC 10-Q: $345M Cash to 2H 2028, R&D Up 51%, New Insider Selling Plans
ORIC is trading near its 52-week low of $7.23 (4.0% above the low).
Summary
ORIC's Q3 10-Q confirms $345.4 million in cash to fund operations into 2H 2028, with R&D up to $43.4 million and the net loss widening to $48.1 million as the first Phase 3 trial ramps. It also discloses new 10b5-1 selling plans for the CEO and CMO.
Key Events · Earnings and Guidance · ORIC
-
Cash Runway Confirmed to 2H 2028
Cash, cash equivalents and investments totaled $345.4 million at September 30, 2026, which management expects to fund the operating plan into the second half of 2028 and past the first Phase 3 rinzimetostat readout.
-
R&D Spend Jumps on Phase 3 Ramp
Q3 R&D rose to $43.4 million from $28.8 million a year earlier, lifting the quarterly net loss to $48.1 million ($0.44 per share) from $32.6 million ($0.33). Nine-month net loss was $125.3 million against an accumulated deficit of $817.6 million.
-
October Safety Review Shows Durable rPFS
The pre-planned October 2026 review reported landmark rPFS of 59% at 8, 9 and 10 months in the post-abiraterone cohort and 71%/59%/59% in the post-AR inhibitor cohort, with no Grade 4 or 5 adverse events attributed to rinzimetostat or darolutamide.
-
CEO and CMO Adopt 10b5-1 Selling Plans
On September 2, 2026, CEO Jacob Chacko adopted a plan for up to 130,100 shares and CMO Pratik Multani for up to 250,100 shares, both running into late 2027.
Analysis · ORIC · Life Sciences
The cash position first disclosed in this morning's earnings 8-K is confirmed here: $345.4 million funds operations into the second half of 2028, past the first Phase 3 rinzimetostat readout. What is new is the cost of that runway. As the Himalayas-1 Phase 3 trial ramps, R&D jumped to $43.4 million in Q3 from $28.8 million a year earlier, pushing the quarterly net loss to $48.1 million from $32.6 million. The filing also carries an October safety and durability update showing landmark rPFS of 59% at 8, 9 and 10 months in the post-abiraterone cohort, in line with the competing PRC2 inhibitor and above standard-of-care benchmarks. Against that, the CEO and CMO both adopted 10b5-1 selling plans on September 2 covering up to 130,100 and 250,100 shares respectively, adding to the insider distribution already visible this quarter.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ORIC was trading at $7.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $779.5M. The 52-week trading range was $7.23 to $14.68. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.